[Off-label use of intravenous immunoglobulin therapy in the treatment of lupus myocarditis: Two case reports and literature review]

Rev Med Interne. 2017 Mar;38(3):204-209. doi: 10.1016/j.revmed.2016.05.005. Epub 2016 Jun 2.
[Article in French]

Abstract

Introduction: Several case reports have reported the benefit of intravenous immunoglobulin therapy in many autoimmune diseases, including systemic lupus erythematosus.

Case reports: Here, we report on two cases of lupus myocarditis treated with high dose of intravenous immunoglobulin. The first patient was a 42-year-old woman who presented with lupus myocarditis that was resistant to corticosteroids and cyclophosphamide, and who was finally successfully treated with a single dose of 2 g/kg of intravenous immunoglobulin. The patient displayed clinical improvement a few days later. The second case - a 43-year-old woman was diagnosed with lupus myocarditis and immunosuppressive drugs were contraindicated because of the context of a recent infective endocarditis. She was treated with repeated dose of 2 g/kg of intravenous immunoglobulin. Clinical improvement was observed and the left ventricular ejection fraction increased from 20 % to 60 % within a few days. We also report 9 similar observations identified from a literature review.

Conclusion: The use of intravenous immunoglobulin in lupus myocarditis is not officially recognized but could be considered as an alternative when conventional therapies have failed or are contraindicated.

Keywords: Immunoglobulines intraveineuses; Intravenous immunoglobulins; Lupus; Myocardite; Myocarditis; Off-label use; Systemic lupus erythematosus; Thérapeutiques hors AMM.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Female
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Lupus Erythematosus, Systemic / complications
  • Lupus Erythematosus, Systemic / therapy*
  • Myocarditis / etiology
  • Myocarditis / therapy*
  • Off-Label Use*
  • Treatment Outcome

Substances

  • Immunoglobulins, Intravenous